Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, our PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. Our preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases.
In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist antibody (Jemperli™ (dostarlimab-gxly)) and an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889).
Enable broad development of our best-in-class immune cell modulators in RA, UC, and AD, respectively.
Generate in vitro and in vivo translational and clinical data to inform the potential differentiation of our molecules from in-class competitors and standard of care, and identify patient populations most likely to have deeper and/or more durable responses by restoring immune balance.
Facilitate the global commercialization of our checkpoint agonists while retaining rights in key therapeutic areas and/or commercial markets to enable us to become a fully integrated discovery, development and commercial organization.
Continue to leverage our research platform to generate potentially best-in-class antibodies against high-value immunological targets.
Board Of Directors
Mr. Faga is a seasoned executive with more than 20 years of industry and advisory experience in the life sciences industry. Most recently, he was the chief operating officer at Mirati Therapeutics responsible for leading the company’s strategy, corporate finance, legal and other business operations.+
Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President.+
Rita Jain, M.D., joined our Board of Directors in April 2023. Dr. Jain is a rheumatologist and currently serves on the Board of Directors of Provention Bio, Inc. and Celldex Therapeutics, and serves on the supervisory board of AM Pharma.+
Dr. Magda Marquet joined our Board of Directors in January 2021. She was the co-CEO of Althea Technologies from 2000 to 2008. She is currently the co-CEO of Alma Life Sciences. LLC, an investment and consulting firm and serves on several Boards of Directors.+
Oleg Nodelman joined our Board of Directors in April 2021. He is the Founder and Portfolio Manager of EcoR1 Capital LLC, a biotech-focused investment advisory firm established in 2013, and has nearly twenty years of experience in biotech investing.+
CEO of Atreca
John Orwin serves on the Board of Directors of Seagen, Inc., Travere Therapeutics and Cargo Therapeutics. He previously served on the Board of Directors of Array BioPharma, Inc. He also currently serves as president and CEO of Atreca, Inc., a clinical-stage biotechnology company, and previously was the CEO of Relypsa, until its acquisition by Galenica, and CEO of Affymax.+
Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008.+
John Schmid has over 35 years of experience in financial and senior management in the biotech industry and has raised over $900 million in private and public equity as well debt financings as a Chief Financial Officer.+
Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas.+
Scientific Advisory Board
Michael Gallatin, Ph.D., is a former Vice President and Scientific Director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of Tadalafil (Cialis®).+
Christopher Hunter, Ph.D., is the Mindy Halikman Heyer President’s Distinguished Chair and former chair of the Department of Pathobiology at the University of Pennsylvania School of Veterinary Medicine. Dr. Hunter’s research has focused on the host’s immune response to infections and the innate events that lead to the development of long term protective immunity mediated […]+
John G. Monroe, Ph.D., is an Emeritus Professor at the Perelman School of Medicine at the University of Pennsylvania. He is a former Senior Director at Genentech where he led the Immunology Discovery Department that is responsible for new target discovery and pre-clinical validation.+
Luisa Salter-Cid, Ph.D., is currently Chief Scientific Officer at Pioneering Medicines. Throughout her career Dr. Salter-Cid has authored of over 90 publications and patents.+
Dolca Thomas, M.D., is currently a venture partner at Samsara BioCapital and serves on the Board of Directors of Allakos Therapeutics and Ventus Therapeutics. Dr. Thomas has extensive experience in both large pharma and biotech.+
10770 Wateridge Circle
San Diego, CA 92121-5801
Phone: (858) 362-6295
Fax: (858) 362-6296